Advertisement
Singapore markets open in 3 hours 48 minutes
  • Straits Times Index

    3,324.53
    +17.09 (+0.52%)
     
  • S&P 500

    5,433.74
    +12.71 (+0.23%)
     
  • Dow

    38,647.10
    -65.11 (-0.17%)
     
  • Nasdaq

    17,667.56
    +59.12 (+0.34%)
     
  • Bitcoin USD

    66,739.92
    -1,434.14 (-2.10%)
     
  • CMC Crypto 200

    1,415.55
    +2.59 (+0.18%)
     
  • FTSE 100

    8,163.67
    -51.81 (-0.63%)
     
  • Gold

    2,319.70
    -35.10 (-1.49%)
     
  • Crude Oil

    77.93
    -0.57 (-0.73%)
     
  • 10-Yr Bond

    4.2380
    -0.0570 (-1.33%)
     
  • Nikkei

    38,720.47
    -156.24 (-0.40%)
     
  • Hang Seng

    18,112.63
    +174.79 (+0.97%)
     
  • FTSE Bursa Malaysia

    1,610.17
    +1.22 (+0.08%)
     
  • Jakarta Composite Index

    6,831.56
    -6,850.10 (-50.07%)
     
  • PSE Index

    6,390.83
    -19.24 (-0.30%)
     

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy

ResMed Inc.
ResMed Inc.

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) --

When:          May 17–22, 2024
Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101
                       Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101

Research:     26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights:

  • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV)
    in Opioid Users – a European Registry

    • Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-B

    • Presented by Jean-Louis Pepin, MD, Grenoble Alpes University, France

  • An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States into 2050

    • Monday, May 20, 9:15 a.m. - 4:15 p.m., SDCC Area C Hall A-B2

    • Presented by Elroy Boers, PhD, ResMed Science Center

  • All-Cause Mortality in Obstructive Sleep Apnea

    • Monday, May 20, 2:15 p.m. - 4:15 p.m., SDCC 32A-B

    • Presented by Atul Malhotra, MD, University of California, San Diego

  • Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare Database

    • Monday, May 20, 2:15 p.m. - 4:15 p.m., SDCC 32A-B

    • Presented by Holger Woehrle, MD, Ulm Lung Centre, Germany

  • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation – Outcomes in Patients with Treatment-Emergent or Persistent Central Sleep Apnea

    • Tuesday, May 21, 2:15 p.m. - 4:15 p.m., Marriott Marquis Pacific Ballroom 15-17

    • Presented by Michael Arzt, MD, Universitätsklinikum Regensburg, Germany

ADVERTISEMENT

Innovation Hub:     Healthcare of Today, Looking Towards Tomorrow: Digital Innovations and Patient Centricity

  • Monday, May 20, 1:15 - 1:35 p.m., SDCC Innovation Hub 4

  • Presented by Monica Mallampalli, Chief Executive Officer at Alliance of Sleep Apnea Partners, and Carlos Nunez, ResMed Chief Medical Officer

Booth #1442:            Featuring ResMed’s latest innovations in respiratory care:

  • AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea

  • AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask

Complete list of ResMed sponsored studies to be presented at ATS 2024:

Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) in opioid users – a European registry

Sunday, May 19, 2024
9:15 AM -11:15 AM

8-year Trends in Obesity, Type 2 Diabetes, and Glucagon-like Peptide-1 (GLP-1) Use in Patients With Obstructive Sleep Apnea

Sunday May 19, 2024
9:15 AM - 11:15 AM

Impact of CPAP Termination on Permanent Work Disability in Obstructive Sleep Apnea: A French Nationwide Alaska Database Analysis

Sunday May 19, 2024
9:15 AM - 4:15 PM

Tailoring Social Support to Improve PAP Therapy Usage in Obstructive Sleep Apnea

Sunday May 19, 2024
9:15 AM - 4:15 PM

Examining Alignment of Patient Medication-taking Behaviors With Inhaler Usage Recommendations in Chronic Obstructive Pulmonary Disease and Asthma

Sunday May 19, 2024
9:15 AM - 4:15 PM

Using Natural Language Processing for Qualitative Research: Insights From a Real-world Analysis

Sunday May 19, 2024
9:15 AM - 4:15 PM

A Qualitative Analysis of Perceptions and Awareness of Air Pollution and Its Health Effects in Asthma Among Asthma-care Professionals Across Southern California

Monday May 20, 2024
9:15 AM - 4:15 PM

An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States Into 2050

Monday May 20, 2024
9:15 AM - 4:15 PM

All-cause Mortality in Obstructive Sleep Apnea: Systematic Literature Review Including Randomised Trials and Confounding Adjusted Non-randomised Controlled Studies and Meta-analysis of Positive Airway Pressure Treatment

Monday May 20, 2024
2:15 PM - 4:15 PM

Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare Database

Monday May 20, 2024
2:15 PM - 4:15 PM

Hypoxic Burden but Not AHI Predicts Risk of Cardiovascular Events: A Secondary Analysis of the RICCADSA Clinical Trial

Monday May 20, 2024
2:15 PM - 4:15 PM

A Digital Quality Improvement Program Delivered By Clinical Pharmacists Can Reduce Acute Care Visits In COPD

Monday May 20, 2024
2:15 PM - 4:15 PM

Hands-on Simulation Training With Home Ventilators Improves PCCM Fellow Understanding of Nocturnal NIV in Chronic Hypercapnia

Monday May 20, 2024
2:15 PM - 4:15 PM

The Economic and Health Burden of COPD in North America Through 2050: A Scenario Analysis Based on Two Large Data Sources

Tuesday May 21, 2024
9:15 AM - 11:15 AM

Impact of long-term domiciliary noninvasive ventilation (NIV) on severe exacerbations and survival in Patients with Chronic Obstructive Pulmonary Disease (COPD): a nationwide cohort study using multistate models

Tuesday May 21, 2024
9:15 AM - 11:15 AM

Nocturnal Hypoxemic Burden and Micro- and Macrovascular Disease in Patients With Type 2 Diabetes

Tuesday May 21, 2024
9:15 AM - 11:15 AM

Risk Factors for Severe Exacerbation Occurrence Among Patients With COPD-OSA Overlap Syndrome Using Bilevel Positive Airway Pressure Therapy

Tuesday May 21, 2024
9:15 AM - 4:15 PM

Adherence to Glucagon-like Peptide-1 Receptor Agonists (GLP-1s) in Obstructive Sleep Apnea Patients With and Without Type 2 Diabetes

Tuesday May 21, 2024
2:15 PM - 4:15 PM

Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) – outcomes in patients with treatment-emergent or persistent central sleep apnea (TE-CSA) in a European registry

Tuesday, May 21, 2024
2:15 PM – 4:15 PM

A Scenario-based Modeling Study to Project the Future Burden of COPD in the United States Accounting for the Effects of E-cigarettes

Tuesday May 21, 2024
2:15 PM - 4:15 PM

The Impact Of Weight Change On Positive Airway Pressure Use In Patients With Obstructive Sleep Apnea And Obesity

Tuesday May 21, 2024
2:15 PM - 4:15 PM

Real World GLP-1 Adherence in Patients with Treated Obstructive Sleep Apnea

Tuesday May 21, 2024
2:15 PM - 4:15 PM

Less REM Sleep Predicts Mortality in Adults With Coronary Artery Disease and Obstructive Sleep Apnea: The RICCADSA Trial

Tuesday May 21, 2024
2:15 PM - 4:15 PM

Gender Specific Differences in a National Sample of Individuals with Comorbid Insomnia, Obstructive Sleep Apnea (OSA), and Depression

Wednesday May 22, 2024
8:15 AM - 10:15 AM

Use of Weight Management Regimens Among Positive Airway Pressure-Treated Patients With Obstructive Sleep Apnea and Obesity

Wednesday May 22, 2024
11:00 AM - 1:00 PM

A Mixed-methods Exploration of Patient Perspectives on Pap Therapy Initiation: Implications for Improved Outreach and Education

Wednesday May 22, 2024
11:00 AM - 1:00 PM


CONTACT: Media questions/requests:         Peter Duckler, +1 (773) 343-3069, pduckler@realchemistry.com Rowena Kelley, +1 (858) 289-7272, rowena.kelley@resmed.com